A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer.

Trial Profile

A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2014

At a glance

  • Drugs Eribulin (Primary) ; Ixabepilone
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Eisai Inc; Eisai Medical Research
  • Most Recent Events

    • 22 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Sep 2012 Results presented at the 2012 Breast Cancer Symposium.
    • 06 Sep 2012 Planned end date changed from 1 Feb 2011 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top